Literature DB >> 29482381

Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome.

Natalia Tovar1, Luis Gerardo Rodríguez-Lobato1, Maria Teresa Cibeira1, Laura Magnano2, Ignacio Isola1, Laura Rosiñol1, Joan Bladé1, Carlos Fernández de Larrea1.   

Abstract

OBJECTIVES: Prognosis of immunoglobulin light-chain (AL) amyloidosis depends mainly on the presence of cardiac involvement and the disease burden. A higher bone marrow plasma cell (BMPC) burden has been recognized as an adverse prognostic factor. The aim of our study was to analyze the correlation between the BMPC infiltration, clinical features and outcomes in patients with AL amyloidosis.
METHODS: The clinical records of 79 patients with AL amyloidosis treated at a single institution.
RESULTS: Median BMPC infiltration at diagnosis was 11% and significantly correlated with the serum free light-chain difference (p < .001). Patients with more than 10% BMPCs had more frequent cardiac involvement (86 vs. 63%; p = .015), a trend towards a higher early mortality (27 vs. 11%; p = .08) and a significantly shorter progression-free survival (PFS) (median of 18 vs. 48 months, p = .02) and overall survival (median of 33 months vs. not reached; p = .046). In the multivariate analysis, a BMPC infiltration over 10% retained its adverse prognostic value for PFS (HR = 2.26; 95% CI, 1.048-4.866; p = .038). The use of new drugs seemed to overcome the negative prognostic impact of a higher BMPC infiltration.
CONCLUSION: Higher BMPC infiltration in AL amyloidosis might be associated with increased systemic organ damage, particularly cardiac involvement and is rarely related to the development of myeloma features.

Entities:  

Keywords:  AL amyloidosis; bone marrow plasma cells; multiple myeloma; prognostic impact

Mesh:

Year:  2018        PMID: 29482381     DOI: 10.1080/13506129.2018.1443439

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  6 in total

1.  Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation.

Authors:  Abdullah S Al Saleh; M Hasib Sidiqi; Eli Muchtar; Francis K Buadi; Angela Dispenzieri; Rahma Warsame; Martha Q Lacy; David Dingli; Wilson I Gonsalves; Taxiarchis V Kourelis; William J Hogan; Suzanne R Hayman; Prashant Kapoor; Shaji K Kumar; Morie A Gertz
Journal:  Biol Blood Marrow Transplant       Date:  2020-05-15       Impact factor: 5.742

2.  Pleural amyloidosis with recurrent pleural effusion and pulmonary embolism: A case report.

Authors:  Yong Dai; Chaoling Liu; Jiaping Chen; Qigang Zeng; Chenxia Duan
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817

3.  Effects of Amyloid Light-Chain Amyloidosis on Clinical Characteristics and Prognosis in Multiple Myeloma: A Single-Center Retrospective Study.

Authors:  Junhui Xu; Mangju Wang; Ye Shen; Miao Yan; Weiwei Xie; Bingjie Wang; Huihui Liu; Xinan Cen
Journal:  Cancer Manag Res       Date:  2021-02-11       Impact factor: 3.989

Review 4.  Biomarkers in AL Amyloidosis.

Authors:  Despina Fotiou; Foteini Theodorakakou; Efstathios Kastritis
Journal:  Int J Mol Sci       Date:  2021-10-09       Impact factor: 5.923

5.  Prognostic Factors of AL-PCMM and AL-MM: A Single-Center Retrospective Study.

Authors:  Junhui Xu; Zhixiang Qiu; Miao Yan; Bingjie Wang; Zhengyang Song; Huihui Liu; Mangju Wang; Xinan Cen
Journal:  Int J Med Sci       Date:  2022-03-14       Impact factor: 3.738

Review 6.  Light Chain Amyloidosis: Epidemiology, Staging, and Prognostication.

Authors:  Kelty R Baker
Journal:  Methodist Debakey Cardiovasc J       Date:  2022-03-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.